<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03864510</url>
  </required_header>
  <id_info>
    <org_study_id>2018:176-31</org_study_id>
    <nct_id>NCT03864510</nct_id>
  </id_info>
  <brief_title>NAFLD in Diabetes Type 2 in Primary Care</brief_title>
  <acronym>EPSONIP</acronym>
  <official_title>Evaluating Prevalence and Severity of NAFLD In Primary Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a
      longitudinal cohort study of patients with T2DM recruited from primary health care centers in
      Östergötland, Sweden. The latest MRI techniques will be used to quantify the amount of
      hepatic fat, inflammation, liver fibrosis and body composition. Each patient will be
      investigated twice with three years apart to determine patients with progressive disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of fatty liver</measure>
    <time_frame>2020</time_frame>
    <description>Number of patients with fatty liver measured with MR-PDFF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of advanced liver disease</measure>
    <time_frame>2020</time_frame>
    <description>Number of patients with advanced liver disease (fibrosis stage &gt; 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The association between physical activity and advanced liver disease (fibrosis &gt;2)</measure>
    <time_frame>2020</time_frame>
    <description>Liver fibrosis measured with MRE and liver biopsy. Physical activity measured with the international fitness scale (IFIS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The association between physical activity and advanced liver disease (fibrosis &gt;2)</measure>
    <time_frame>2020</time_frame>
    <description>Liver fibrosis measured with MRE and liver biopsy. Physical activity measured with Actigraph GT3X (accelerometer)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The association between fitness and advanced liver disease (fibrosis &gt;2)</measure>
    <time_frame>2020</time_frame>
    <description>Liver fibrosis measured with MRE and liver biopsy. Fitness measured with the six minute walk test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic factors associated with advanced liver disease (fibrosis &gt;2)</measure>
    <time_frame>2020</time_frame>
    <description>Liver fibrosis measured with MRE and liver biopsy. Genes to be analyzed: PNPLA3, TM6SF2, MBOAT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health economic model for disease management</measure>
    <time_frame>2025</time_frame>
    <description>Markow model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that develop symptoms of end-stage liver disease</measure>
    <time_frame>2030</time_frame>
    <description>Symptoms of end-stage liver disease (ascites, encepahopathy, varices, HCC) or liver related Death will be recorded through chart review</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>NAFLD</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma, DNA, RNA, liver tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutively enrolled patients with diabetes type 2 in primary care.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes type 2

          -  Age 35-75 year

        Exclusion Criteria:

          -  Contraindication to MR

          -  Alcohol dependance

          -  Previously diagnosed liver cirrhosis

          -  Previously known liver disease (other than fatty liver)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattias Ekstedt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LiU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mattias Ekstedt, MD, PhD</last_name>
    <phone>+46(0)709296267</phone>
    <email>mattias.ekstedt@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stergios Kechagias, MD, PhD</last_name>
    <email>stergios.kechagias@liu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ekholmen primary health care centre</name>
      <address>
        <city>Linköping</city>
        <state>Swedish</state>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bergram, MD</last_name>
      <email>martin.bergram@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Åby primary health care centre</name>
      <address>
        <city>Norrköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Iredahl, MD, PhD</last_name>
      <email>fredrik.iredahl@regionostergotland.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Linkoeping University</investigator_affiliation>
    <investigator_full_name>Mattias Ekstedt</investigator_full_name>
    <investigator_title>Senior Lecturer/Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

